JP Morgan Chase
OCUL icon

JP Morgan Chase’s Ocular Therapeutix OCUL Stock Holding History

JP Morgan Chase’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,000
Closed -$255K – 7642
2024
Q1 		$255K Buy
+28,000
New +$199K ﹤0.01% 5219

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase's OCUL Position: Q1 2026 in Review

JP Morgan Chase reduced its Ocular Therapeutix (OCUL) stake by 5.4% in Q1 2026, selling an estimated $282K and leaving 520,663 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

JP Morgan Chase first reported a position in OCUL in Q1 2017 and has held it in 37 quarters since. The position peaked at $6.68M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • JP Morgan Chase held 520,663 shares of Ocular Therapeutix worth $3.85M as of Q1 2026.
  • JP Morgan Chase sold 29,606 Ocular Therapeutix shares in Q1 2026, an estimated $282K.
  • Ocular Therapeutix made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3564 holding.
  • JP Morgan Chase first reported a position in Ocular Therapeutix in Q1 2017 and has held it in 37 quarters since.
  • JP Morgan Chase's Ocular Therapeutix position peaked at $6.68M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.